# Vaxcyte, Inc.: financial statements, quarterly

PCVX · Nasdaq · CIK 1649094 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pcvx.md) · [Financials](/companies/pcvx/financials.md) · [Filings](/companies/pcvx/filings.md) · [Insiders](/companies/pcvx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pcvx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [97.4](/filings/0001649094-24-000097.md) | [104 d](/filings/0001649094-26-000007.md) | [94.6](/filings/0001649094-25-000074.md) | [132](/filings/0001649094-25-000098.md) | [117](/filings/0001649094-25-000114.md) | [134 d](/filings/0001649094-26-000007.md) | [148](/filings/0001649094-26-000017.md) | [194](/filings/0001649094-26-000043.md) | [210](/filings/0001649094-25-000114.md) | [242 d](/filings/0001649094-26-000007.md) | [313](/filings/0001649094-26-000017.md) | [268](/filings/0001649094-26-000043.md) |
| Operating income | $m | [(113)](/filings/0001649094-24-000097.md) | [(197) d](/filings/0001649094-26-000007.md) | [(114)](/filings/0001649094-25-000074.md) | [(153)](/filings/0001649094-25-000098.md) | [(140)](/filings/0001649094-25-000114.md) | [(162) d](/filings/0001649094-26-000007.md) | [(181)](/filings/0001649094-26-000017.md) | [(226)](/filings/0001649094-26-000043.md) | [(242)](/filings/0001649094-25-000114.md) | [(274) d](/filings/0001649094-26-000007.md) | [(346)](/filings/0001649094-26-000017.md) | [(303)](/filings/0001649094-26-000043.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-059395.md) | [0.0 d](/filings/0000950170-24-021145.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-23-059395.md) | [0.0 d](/filings/0001649094-26-000007.md) | [0.0](/filings/0001649094-25-000074.md) | [0.0](/filings/0001649094-25-000098.md) | [0.0](/filings/0001649094-25-000114.md) | [0.0 d](/filings/0001649094-26-000007.md) | [0.0](/filings/0001649094-26-000017.md) | [0.0](/filings/0001649094-26-000043.md) | [0.0](/filings/0001649094-25-000114.md) | [0.0 d](/filings/0001649094-26-000007.md) | [0.0](/filings/0001649094-26-000017.md) | [0.0](/filings/0001649094-26-000043.md) |
| Net income | $m | [(92.7)](/filings/0001649094-24-000097.md) | [(181) d](/filings/0001649094-26-000007.md) | [(95.0)](/filings/0001649094-25-000114.md) | [(129)](/filings/0001649094-25-000114.md) | [(103)](/filings/0001649094-25-000114.md) | [(137) d](/filings/0001649094-26-000007.md) | [(141)](/filings/0001649094-26-000043.md) | [(167)](/filings/0001649094-26-000043.md) | [(213)](/filings/0001649094-25-000114.md) | [(247) d](/filings/0001649094-26-000007.md) | [(321)](/filings/0001649094-26-000043.md) | [(284)](/filings/0001649094-26-000043.md) |
| Diluted EPS | $ per share | [(0.91)](/filings/0001649094-24-000097.md) | not reported | [(0.85)](/filings/0001649094-25-000074.md) | [(1.10)](/filings/0001649094-25-000098.md) | [(0.83)](/filings/0001649094-25-000114.md) | not reported | [(1.04)](/filings/0001649094-26-000017.md) | [(1.22)](/filings/0001649094-26-000043.md) | [(1.56)](/filings/0001649094-25-000114.md) | not reported | [(2.30)](/filings/0001649094-26-000017.md) | [(1.97)](/filings/0001649094-26-000043.md) |
| Basic EPS | $ per share | [(0.91)](/filings/0001649094-24-000097.md) | not reported | [(0.85)](/filings/0001649094-25-000074.md) | [(1.10)](/filings/0001649094-25-000098.md) | [(0.83)](/filings/0001649094-25-000114.md) | not reported | [(1.04)](/filings/0001649094-26-000017.md) | [(1.22)](/filings/0001649094-26-000043.md) | [(1.56)](/filings/0001649094-25-000114.md) | not reported | [(2.30)](/filings/0001649094-26-000017.md) | [(1.97)](/filings/0001649094-26-000043.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [545](/filings/0000950170-23-059395.md) | [397](/filings/0001649094-26-000007.md) | [612](/filings/0001649094-25-000074.md) | [519](/filings/0001649094-25-000098.md) | [1,050](/filings/0001649094-25-000114.md) | [388](/filings/0001649094-26-000007.md) | [347](/filings/0001649094-26-000017.md) | [307](/filings/0001649094-26-000043.md) | [281](/filings/0001649094-25-000114.md) | [174](/filings/0001649094-26-000043.md) | [261](/filings/0001649094-26-000017.md) | [183](/filings/0001649094-26-000043.md) |
| Current assets | $m | [1,295](/filings/0000950170-23-059395.md) | [1,096](/filings/0001649094-25-000028.md) | [1,517](/filings/0001628280-24-021677.md) | [1,481](/filings/0001649094-24-000052.md) | [2,214](/filings/0001649094-24-000097.md) | [1,788](/filings/0001649094-26-000007.md) | [1,717](/filings/0001649094-25-000074.md) | [1,716](/filings/0001649094-25-000098.md) | [1,767](/filings/0001649094-25-000114.md) | [1,627](/filings/0001649094-26-000043.md) | [1,813](/filings/0001649094-26-000017.md) | [1,553](/filings/0001649094-26-000043.md) |
| Total assets | $m | [1,496](/filings/0000950170-23-059395.md) | [1,408](/filings/0001649094-25-000028.md) | [2,091](/filings/0001628280-24-021677.md) | [2,087](/filings/0001649094-24-000052.md) | [3,560](/filings/0001649094-24-000097.md) | [3,511](/filings/0001649094-26-000007.md) | [3,378](/filings/0001649094-25-000074.md) | [3,305](/filings/0001649094-25-000098.md) | [3,172](/filings/0001649094-25-000114.md) | [3,003](/filings/0001649094-26-000043.md) | [3,348](/filings/0001649094-26-000017.md) | [3,138](/filings/0001649094-26-000043.md) |
| Current liabilities | $m | [85.6](/filings/0000950170-23-059395.md) | [145](/filings/0001649094-25-000028.md) | [87.1](/filings/0001628280-24-021677.md) | [82.8](/filings/0001649094-24-000052.md) | [124](/filings/0001649094-24-000097.md) | [140](/filings/0001649094-26-000007.md) | [97.0](/filings/0001649094-25-000074.md) | [154](/filings/0001649094-25-000098.md) | [200](/filings/0001649094-25-000114.md) | [206](/filings/0001649094-26-000043.md) | [242](/filings/0001649094-26-000017.md) | [271](/filings/0001649094-26-000043.md) |
| Total liabilities | $m | [93.3](/filings/0000950170-23-059395.md) | [167](/filings/0001649094-25-000028.md) | [107](/filings/0001628280-24-021677.md) | [101](/filings/0001649094-24-000052.md) | [142](/filings/0001649094-24-000097.md) | [205](/filings/0001649094-26-000007.md) | [178](/filings/0001649094-25-000074.md) | [234](/filings/0001649094-25-000098.md) | [279](/filings/0001649094-25-000114.md) | [317](/filings/0001649094-26-000043.md) | [352](/filings/0001649094-26-000017.md) | [380](/filings/0001649094-26-000043.md) |
| Shareholders' equity | $m | [1,403](/filings/0001649094-24-000097.md) | [1,240](/filings/0001649094-26-000007.md) | [1,984](/filings/0001649094-25-000114.md) | [1,986](/filings/0001649094-25-000114.md) | [3,418](/filings/0001649094-25-000114.md) | [3,306](/filings/0001649094-26-000043.md) | [3,200](/filings/0001649094-26-000043.md) | [3,071](/filings/0001649094-26-000043.md) | [2,893](/filings/0001649094-25-000114.md) | [2,686](/filings/0001649094-26-000043.md) | [2,996](/filings/0001649094-26-000043.md) | [2,758](/filings/0001649094-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(57.5) d](/filings/0001649094-24-000097.md) | [(129) d](/filings/0001649094-26-000007.md) | [(159)](/filings/0001649094-25-000074.md) | [(121) d](/filings/0001649094-25-000098.md) | [(60.7) d](/filings/0001649094-25-000114.md) | [(111) d](/filings/0001649094-26-000007.md) | [(166)](/filings/0001649094-26-000017.md) | [(121) d](/filings/0001649094-26-000043.md) | [(143) d](/filings/0001649094-25-000114.md) | [(225) d](/filings/0001649094-26-000007.md) | [(281)](/filings/0001649094-26-000017.md) | [(232) d](/filings/0001649094-26-000043.md) |
| Capital expenditure | $m | [7.3 d](/filings/0001649094-24-000097.md) | [5.3 d](/filings/0001649094-26-000007.md) | [5.7](/filings/0001649094-25-000074.md) | [7.8 d](/filings/0001649094-25-000098.md) | [4.9 d](/filings/0001649094-25-000114.md) | [4.0 d](/filings/0001649094-26-000007.md) | [5.4](/filings/0001649094-26-000017.md) | [1.8 d](/filings/0001649094-26-000043.md) | [3.8 d](/filings/0001649094-25-000114.md) | [2.7 d](/filings/0001649094-26-000007.md) | [2.1](/filings/0001649094-26-000017.md) | [4.3 d](/filings/0001649094-26-000043.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [62.0](/filings/0000950170-23-059395.md) | [86.2](/filings/0001628280-24-021677.md) | [98.1](/filings/0001649094-24-000052.md) | [102](/filings/0001649094-24-000097.md) | [112](/filings/0001649094-25-000074.md) | [117](/filings/0001649094-25-000098.md) | [124](/filings/0001649094-25-000114.md) | [136](/filings/0001649094-26-000017.md) | [136](/filings/0001649094-26-000043.md) | [136](/filings/0001649094-25-000114.md) | [140](/filings/0001649094-26-000017.md) | [144](/filings/0001649094-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 148,805,278 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001649094-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.